Iwatsuki S, Dvorchik I, Marsh J W, Madariaga J R, Carr B, Fung J J, Starzl T E
Department of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, PA 15213, USA.
J Am Coll Surg. 2000 Oct;191(4):389-94. doi: 10.1016/s1072-7515(00)00688-8.
The current staging system of hepatocellular carcinoma established by the International Union Against Cancer and the American Joint Committee on Cancer does not necessarily predict the outcomes after hepatic resection or transplantation.
Various clinical and pathologic risk factors for tumor recurrence were examined on 344 consecutive patients who received hepatic transplantation in the presence of nonfibrolamellar hepatocellular carcinoma to establish a reliable risk scoring system.
Multivariate analysis identified three factors as independently significant poor prognosticators: 1) bilobarly distributed tumors, 2) size of the greatest tumor (2 to 5 cm and > 5 cm), and 3) vascular invasion (microscopic and macroscopic). Prognostic risk score (PRS) of each patient was calculated from the relative risks of multivariate analysis. The patients were grouped into five grades of tumor recurrence risk: grade 1: PRS = 0 to < 7.5; grade 2: PRS = 7.5 to < or = 11.0; grade 3: PRS > 11.0 to 15.0; grade 4: PRS > or = 15.0; and grade 5: positive node, metastasis, or margin. The proposed PRS system correlated extremely well with tumor-free survival after liver transplantation (100%, 61%, 40%, 5%, and 0%, from grades 1 to 5, respectively, at 5 years), but current pTNM staging did not.
国际抗癌联盟和美国癌症联合委员会制定的现行肝细胞癌分期系统不一定能预测肝切除或肝移植后的预后。
对344例接受非纤维板层型肝细胞癌肝移植的连续患者,研究了肿瘤复发的各种临床和病理危险因素,以建立一个可靠的风险评分系统。
多因素分析确定了三个独立的显著不良预后因素:1)双叶分布肿瘤;2)最大肿瘤大小(2至5厘米和>5厘米);3)血管侵犯(显微镜下和肉眼可见)。根据多因素分析的相对风险计算每位患者的预后风险评分(PRS)。患者被分为五个肿瘤复发风险等级:1级:PRS = 0至<7.5;2级:PRS = 7.5至<或=11.0;3级:PRS>11.0至15.0;4级:PRS>或=15.0;5级:阳性淋巴结、转移或切缘阳性。所提出的PRS系统与肝移植后的无瘤生存率相关性极佳(5年时,1至5级分别为100%、61%、40%、5%和0%),但现行的pTNM分期则不然。
1)1级和2级患者行肝移植可有效治疗;2)4级和5级患者不是肝移植的合适候选者;3)1级患者不能从辅助化疗中获益。